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Stress will kill you anyway!
Alexia Belavgeni1, Stefan R. Bornstein2 and Andreas Linkermann 1,3
Adrenocortical carcinomas are devastating cancers, expressing high levels of glutathione peroxidase 4 (GPX4). Therefore,
it was recently suggested that these tumors might be therapeutically targeted by inducing ferroptosis. In this issue of Cell
Death and Disease, Weigand et al. describe the organ-specific production of steroid hormones as a potential culprit for the
exquisite sensitivity of these cancers to ferroptosis.
Ferroptosis, like all necrotic-type cell death pathways,
causes an immune reaction referred to as necroin-
flammation1. In the heart, ferroptosis results in rapid
neutrophil infiltration2, a response that would ideally be
directed against cancers. This is of particular importance
when current strategies hardly provide tumor regression,
and cancers are treated with nonspecific drugs, which
induce massive side effects. Adrenocortical carcinomas
(ACCs) are just like that. The oncologist’s despair may
best be exemplified by common prescription of mitotane,
a nonspecific chemotherapeutic derived from the pesti-
cide DDT (1,1-(dichlorobiphenyl)-2,2-dichloroethane)
with unknown mechanisms of action.
The association of hormone production and the
increase of reactive oxygen species (ROS) in the adrenal
gland lead to the hypothesis of a tightly balanced redox
system. Given the current knowledge on ferroptosis,
Weigand et al.3 questioned how this endocrine system
might evade cell death upon tumorigenesis. More speci-
fically, with the help of a public database, the Human
Proteome Map, it was demonstrated that the adrenal
gland expresses a variety of genes, linked to ferroptosis,
including glutathione peroxidase (GPX4), lysopho-
sphatidylcholine acyltransferase 3 (LPCAT3), and Acyl-
CoA synthase long-chain family member 4 (ACSL4). The
expression of GPX4 and ACSL4, two proteins that are
centrally involved in the regulation of ferroptosis, was
confirmed in human normal adrenal glands (nAGs),
adrenocortical adenomas (ACAs), and adrenocortical
carcinomas (ACCs). ACCs showed a significantly higher
expression of GXP4 mRNA expression compared with
nAGs, further underlining the susceptibility of the adrenal
gland to ferroptosis. Peroxidation of high levels of ara-
chidonic acid and adrenic acid, both of which are long-
chain polyunsaturated fatty acids (PUFAs), was detected
in the cortex of nAGs, ACA, and ACC samples.
Cell culture systems are frequently used to study the
adrenal gland and its malignancies. A well-known and
established human ACC cell line is NCI-H295R that was
employed in this study alongside with the less frequently
investigated CU-ACC1 and CU-ACC2 cell lines. By wes-
tern blot analysis, all of these cell lines were demonstrated
to express significant amounts of ACSL4 and GPX4. The
above-mentioned findings were in keeping with the con-
cept of the adrenal gland to be sensitive toward ferroptosis.
Induction of ferroptosis is routinely performed by sti-
mulation with several small molecules that may be clas-
sified as four categories of ferroptosis inducers (FINs).
The two most commonly used FINs are type I FINs, e.g.,
erastin (inhibitors of system Xc-) and type II FINs, such as
RSL3, that directly inhibit GPX4. Weigand et al. chal-
lenged all three ACC cell lines with different concentra-
tions of erastin, but failed to induce significant amounts of
ferroptosis. However, NCI-H295R, CU-ACC1, and CU-
ACC2 were highly sensitive to RSL3 treatment, while
non-steroidogenic cell lines were less sensitive to RSL3
treatment.
Hormone production is one of the hallmarks of the
adrenal gland. Testing the hypothesis of a potential con-
nection between the hormone production pathways and
ferroptosis (Fig. 1), Weigand et al. challenged the ACC
cell lines with RSL3 in the presence of the pan-steroid
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inhibitor ketoconazole. As expected, ketoconazole
impaired hormone production. Remarkably, at con-
centrations of 25 μΜ, it significantly inhibited RSL3-
induced cell death of all ACC cell lines.
Steroid synthesis involves several enzymes, including
11-β-hydroxylase that is responsible for the generation of
cortisol and corticosterone from 11-deoxycortisol and
deoxycorticosterone, respectively. A more specific inhi-
bitor of 11-β-hydroxylase, metyrapone, did not affect the
sensitivity to RSL3-mediated ferroptosis in various con-
centrations investigated.
As discussed above, the mechanism of action of mito-
tane remains elusive. The authors report that increased
concentrations of mitotane-induced cell death of the NCI-
H295R cells showed a concentration-dependent increase
in lipid peroxidation. This interesting finding resulted in
the hypothesis of a ferroptotic type of cell death induced
by mitotane. Therefore, liproxstatin-1, a ferroptosis inhi-
bitor, was used in different concentrations in parallel with
different concentrations of mitotane, and all ACC cell
lines were treated. Nevertheless, none of the investigated
combinations reversed mitotane-induced cell death.
Given the high sensitivity of the ACC cell lines to RSL3,
the authors of this study investigated potential synergistic
effects of mitotane and RSL3 treatment. Significant
changes of cell death induction were observed only in the
co-treatment of NCI-H295R and CU-ACC2 cell lines with
mitotane and RSL3, compared with monotherapy.
In summary, two recent publications, one published in
Cell Death and Disease3, and the other in the Proceedings
of the National Academy of Sciences (PNAS)4, describe
ACC sensitivity to ferroptosis induction. Both groups
consistently found high protein expression levels of GPX4
in those cells. GPX4 was known to encompass anti-
ferroptotic properties, and it was therefore expected that
these tumors are sensitive to ferroptosis induction by the
GPX4 inhibitor RSL35. Besides GPX4, however, other
breaks on ferroptosis have recently been reported. Most
prominently, the discovery of FSP1 (ferroptosis-sensitiz-
ing protein 1, previously known as apoptosis-inhibiting
factor m2 (AIFM2)) as a GSH-independent inhibitor of
ferroptosis6,7, will give rise to further investigation in
ACCs. Exploration of the sensitivity of ACCs toward
other types of FINs will follow soon. Finally, both groups
reported the inability of ferroptosis inhibitors to block the
mitotane-induced cell death. These findings indicate
another type of necrotic, potentially toxic, cell death.
In conclusion, the discovery of ACCs as ferroptosis-
sensitive tumors will hopefully trigger further investiga-
tion in primary tumor samples. It is, however, not trivial
to detect ferroptosis in human tissues8. Nonetheless, we
strongly support to test ferroptosis inducers as ultima
ratio for patients with metastasized ACCs as soon as they
are available for clinical application.
Author details
1Division of Nephrology, University Hospital Carl Gustav Carus at the
Technische Universität Dresden, 01307 Dresden, Germany. 2Department of
Internal Medicine III, University Hospital Carl Gustav Carus at the Technische
Universität Dresden, 01307 Dresden, Germany. 3Biotechnology Center,
Technische Universität Dresden, 01307 Dresden, Germany
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Received: 22 January 2020 Revised: 20 March 2020 Accepted: 25 March
2020
Fig. 1 Steroid-producing adrenocortical carcinomas are sensitive to ferroptosis induction. Steroid production in the adrenal gland is
associated with high levels of intracellular reactive oxygen species that originate from the respiratory chain and may trigger Fenton reactions and
finally cause lipid peroxidation. Glutathione peroxidase 4 (GPX4), a master regulator of ferroptosis, inhibits lipid peroxidation in such cells. During
tumorigenesis, steroid-producing adrenocortical carcinomas (ACCs) may become partially dependent on GPX4 expression. A targeted therapy with
RSL3, a compound that covalently binds to the active center of GPX4, results in dysfunction of the anti-ferroptosis protein and thereby kills the cancer
by ferroptosis. DAMP release from the ferroptotic tumor, in addition, might potentiate the antitumor effect by recruiting neutrophils and other
immune cells to reject the tumor tissue.
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